Literature DB >> 25708247

MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7.

Quan Li1, Xiang-Mei Qiu1, Qing-Han Li1, Xiao-Yan Wang1, Li Li1, Min Xu1, Min Dong1, Yan-Bing Xiao1.   

Abstract

MicroRNAs (miRNAs) are frequently dysregulated in human cancers and can act as potent oncogenes or tumor suppressor genes. Aberrant expression of miR-424 has been identified in some types of cancer, however, its expression and potential biologic role in endometrial cancer are remains to be determined. In the present study, we demonstrated that miR-424 was downregulated in human endometrial cancer and suppressed growth of the human Ishikawa and HEC-1B endometrial cancer cell lines. Bioinformatics analysis indicated that E2F7 was a putative target of miR-424. In a luciferase reporter system, we confirmed that E2F7 was a direct target gene of miR-424. Furthermore, knockdown of E2F7 inhibited Ishikawa and HEC-1B cell growth. These findings indicate that miR-424 targets the E2F7 transcript and suppresses endometrial cancer cell growth, suggesting that miR-424 has a tumor suppressive role in human endometrial cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25708247     DOI: 10.3892/or.2015.3812

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  29 in total

1.  MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation.

Authors:  Chen Jin; Minhong Li; Yian Ouyang; Zhigang Tan; Yugang Jiang
Journal:  J Neurooncol       Date:  2017-05-15       Impact factor: 4.130

Review 2.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

3.  MiR-195 inhibits migration, invasion and epithelial-mesenchymal transition (EMT) of endometrial carcinoma cells by targeting SOX4.

Authors:  Xiaomeng Zhao; Lili Dai; Qifang Yue; Hua Wang; X U Wang; Yuan Li; Ran Chen
Journal:  J Biosci       Date:  2019-12       Impact factor: 1.826

4.  Decreased expression of serum miR-424 correlates with poor prognosis of patients with hepatocellular carcinoma.

Authors:  Huaiqi Yao; Xuanzhi Liu; Suzuan Chen; Wei Xia; Xiaojun Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Targeted Silencing of S100A8 Gene by miR-24 to Increase Chemotherapy Sensitivity of Endometrial Carcinoma Cells to Paclitaxel.

Authors:  Bin Lang; Chao Shang; Lirong Meng
Journal:  Med Sci Monit       Date:  2016-06-09

6.  Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.

Authors:  Peixin Dong; Kei Ihira; Ying Xiong; Hidemichi Watari; Sharon J B Hanley; Takahiro Yamada; Masayoshi Hosaka; Masataka Kudo; Junming Yue; Noriaki Sakuragi
Journal:  Oncotarget       Date:  2016-04-12

7.  LncRNA OIP5-AS1/cyrano sponges RNA-binding protein HuR.

Authors:  Jiyoung Kim; Kotb Abdelmohsen; Xiaoling Yang; Supriyo De; Ioannis Grammatikakis; Ji Heon Noh; Myriam Gorospe
Journal:  Nucleic Acids Res       Date:  2016-01-26       Impact factor: 16.971

8.  MicroRNA-424/E2F6 feedback loop modulates cell invasion, migration and EMT in endometrial carcinoma.

Authors:  Zheng Lu; Zhou Nian; Zhang Jingjing; Luo Tao; Li Quan
Journal:  Oncotarget       Date:  2017-12-13

9.  Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.

Authors:  Sushmita Bose Nandy; Alexis Orozco; Rebecca Lopez-Valdez; Rene Roberts; Ramadevi Subramani; Arunkumar Arumugam; Alok Kumar Dwivedi; Viktoria Stewart; Gautham Prabhakar; Stephanie Jones; Rajkumar Lakshmanaswamy
Journal:  Br J Cancer       Date:  2017-10-12       Impact factor: 7.640

10.  IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma.

Authors:  Hsuan-Yu Peng; Shih-Sheng Jiang; Jenn-Ren Hsiao; Michael Hsiao; Yuan-Ming Hsu; Guan-Hsun Wu; Wei-Min Chang; Jang-Yang Chang; Shiow-Lian Catherine Jin; Shine-Gwo Shiah
Journal:  Mol Oncol       Date:  2016-03-22       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.